Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sanofi launches $69 per share bid for Genzyme; $17.5bn value

Executive Summary

Confirming speculation that began over a month ago, Sanofi-Aventis has made public a non-binding offer to acquire Genzyme Corp. The Big Pharma says it will pay $69 for each of Genzyme's outstanding shares, valuing the deal at about $17.5bn. Genzyme's board was quick to reject the offer, claiming that it dramatically undervalues the company.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Full Acquisition
    • Payment Includes Cash
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register